350 related articles for article (PubMed ID: 29791480)
1. Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.
Liu J; Bayer JD; Aschar-Sobbi R; Wauchop M; Spears D; Gollob M; Vigmond EJ; Tsushima R; Backx PH; Chauhan VS
PLoS One; 2018; 13(5):e0197273. PubMed ID: 29791480
[TBL] [Abstract][Full Text] [Related]
2. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH
Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085
[TBL] [Abstract][Full Text] [Related]
3. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
Ruan Y; Liu N; Bloise R; Napolitano C; Priori SG
Circulation; 2007 Sep; 116(10):1137-44. PubMed ID: 17698727
[TBL] [Abstract][Full Text] [Related]
4. Further Insights in the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction Defect.
Veltmann C; Barajas-Martinez H; Wolpert C; Borggrefe M; Schimpf R; Pfeiffer R; Cáceres G; Burashnikov E; Antzelevitch C; Hu D
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27381756
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome.
Nasilli G; Yiangou L; Palandri C; Cerbai E; Davis RP; Verkerk AO; Casini S; Remme CA
Europace; 2023 Jun; 25(6):. PubMed ID: 37369559
[TBL] [Abstract][Full Text] [Related]
6. A sodium channel pore mutation causing Brugada syndrome.
Pfahnl AE; Viswanathan PC; Weiss R; Shang LL; Sanyal S; Shusterman V; Kornblit C; London B; Dudley SC
Heart Rhythm; 2007 Jan; 4(1):46-53. PubMed ID: 17198989
[TBL] [Abstract][Full Text] [Related]
7. Reduced current density, partially rescued by mexiletine, and depolarizing shift in activation of SCN5A W374G channels as a cause of severe form of Brugada syndrome.
Nakajima T; Dharmawan T; Kawabata-Iwakawa R; Tamura S; Hasegawa H; Kobari T; Ota M; Tange S; Nishiyama M; Kaneko Y; Kurabayashi M
Ann Noninvasive Electrocardiol; 2021 May; 26(3):e12828. PubMed ID: 33463855
[TBL] [Abstract][Full Text] [Related]
8. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3.
Ruan Y; Denegri M; Liu N; Bachetti T; Seregni M; Morotti S; Severi S; Napolitano C; Priori SG
Circ Res; 2010 Apr; 106(8):1374-83. PubMed ID: 20339117
[TBL] [Abstract][Full Text] [Related]
9. Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation.
Zhu W; Mazzanti A; Voelker TL; Hou P; Moreno JD; Angsutararux P; Naegle KM; Priori SG; Silva JR
Circ Res; 2019 Feb; 124(4):539-552. PubMed ID: 30566038
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S
Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495
[TBL] [Abstract][Full Text] [Related]
11. A heterozygous deletion mutation in the cardiac sodium channel gene SCN5A with loss- and gain-of-function characteristics manifests as isolated conduction disease, without signs of Brugada or long QT syndrome.
Zumhagen S; Veldkamp MW; Stallmeyer B; Baartscheer A; Eckardt L; Paul M; Remme CA; Bhuiyan ZA; Bezzina CR; Schulze-Bahr E
PLoS One; 2013; 8(6):e67963. PubMed ID: 23840796
[TBL] [Abstract][Full Text] [Related]
12. A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant.
Gando I; Campana C; Tan RB; Cecchin F; Sobie EA; Coetzee WA
J Mol Cell Cardiol; 2020 Jul; 144():1-11. PubMed ID: 32339567
[TBL] [Abstract][Full Text] [Related]
13. Characterization and mechanisms of action of novel NaV1.5 channel mutations associated with Brugada syndrome.
Calloe K; Refaat MM; Grubb S; Wojciak J; Campagna J; Thomsen NM; Nussbaum RL; Scheinman MM; Schmitt N
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):177-84. PubMed ID: 23424222
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of a novel frameshift mutation in the C-terminus of the Nav1.5 channel underlying a Brugada syndrome with variable expression in a Spanish family.
Dolz-Gaitón P; Núñez M; Núñez L; Barana A; Amorós I; Matamoros M; Pérez-Hernández M; González de la Fuente M; Alvarez-López M; Macías-Ruiz R; Tercedor-Sánchez L; Jiménez-Jáimez J; Delpón E; Caballero R; Tamargo J
PLoS One; 2013; 8(11):e81493. PubMed ID: 24363796
[TBL] [Abstract][Full Text] [Related]
15. Flecainide provocation reveals concealed brugada syndrome in a long QT syndrome family with a novel L1786Q mutation in SCN5A.
Kanters JK; Yuan L; Hedley PL; Stoevring B; Jons C; Bloch Thomsen PE; Grunnet M; Christiansen M; Jespersen T
Circ J; 2014; 78(5):1136-43. PubMed ID: 24599044
[TBL] [Abstract][Full Text] [Related]
16. Enhanced fast-inactivated state stability of cardiac sodium channels by a novel voltage sensor SCN5A mutation, R1632C, as a cause of atypical Brugada syndrome.
Nakajima T; Kaneko Y; Saito A; Ota M; Iijima T; Kurabayashi M
Heart Rhythm; 2015 Nov; 12(11):2296-304. PubMed ID: 26031372
[TBL] [Abstract][Full Text] [Related]
17. Enhanced closed-state inactivation of mutant cardiac sodium channels (SCN5A N1541D and R1632C) through different mechanisms.
Dharmawan T; Nakajima T; Iizuka T; Tamura S; Matsui H; Kaneko Y; Kurabayashi M
J Mol Cell Cardiol; 2019 May; 130():88-95. PubMed ID: 30935997
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
Stutzman MJ; Gao X; Kim M; Ye D; Zhou W; Tester DJ; Giudicessi JR; Shannon K; Ackerman MJ
Heart Rhythm; 2023 May; 20(5):709-717. PubMed ID: 36731785
[TBL] [Abstract][Full Text] [Related]
19. Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel.
Wang DW; Crotti L; Shimizu W; Pedrazzini M; Cantu F; De Filippo P; Kishiki K; Miyazaki A; Ikeda T; Schwartz PJ; George AL
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):370-8. PubMed ID: 19808432
[TBL] [Abstract][Full Text] [Related]
20. Arrhythmogenic Biophysical Phenotype for SCN5A Mutation S1787N Depends upon Splice Variant Background and Intracellular Acidosis.
Hu RM; Tan BH; Tester DJ; Song C; He Y; Dovat S; Peterson BZ; Ackerman MJ; Makielski JC
PLoS One; 2015; 10(4):e0124921. PubMed ID: 25923670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
